VARGATEF |
BIBF1120 |
NINTEDANIB |
OFEV |
BIBF-1120 |
INTEDANIB |
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE |
OFEV® |
VARGATEF® |
BIBF 1120 |
drugbank:09079 |
chembl:CHEMBL502835 |
chemidplus:656247-17-5 |
rxcui:1592737 |
pubchem.compound:9809715 |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | antifibrotic agents |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates (strength unknown) |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | oct1 inhibitors |
Drug Categories | oct1 substrates |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | tyrosine kinase inhibitors |
Drug Categories | ugt1a1 substrates |
inhibitor (inhibitory) |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Response Type | resistant |
Indication/Tumor Type | urinary bladder cancer |
Evidence Type | Actionable |
n/a |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | BIBF-1120,Vargatef |
Notes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
n/a |
Drug family | Pan-TK inhibitor |
Alteration | RET__. |
inhibitor (inhibitory) |
Notes |
NINTEDANIB | DrugBank Drug Name |
656247-17-5 | CAS Number |
Ofev | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antifibrotic agents |
BIBF1120 | Development Name |
NINTEDANIB | Generic Name |
VARGATEF | Trade Name |
Drug Class | Kinase Inhibitors |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL502835 | ChEMBL Drug ID |
NINTEDANIB | Primary Drug Name |
VARGATEF | Drug Trade Name |
BIBF 1120 | Drug Synonym |
D09HNV | TTD Drug ID |
NINTEDANIB | GuideToPharmacology Ligand Name |